Beyond Air Inc (XAIR) Stock Price, Quote & News

Company Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiol...

Industry: Medical Devices

Sector: Healthcare

Phone: 516 665 8200

Website: www.beyondair.net

Address:

900 Stewart Avenue, Suite 301, Garden City, United States

RunningMoons Mar. 4 at 3:15 PM

$MLGO $CREG $PAPL $XAIR u

0 · Reply

VernCapital Mar. 3 at 1:53 PM

$XAIR I’m not sure which part of dead for the rest of 2026 people don’t understand.

1 · Reply

DirtDobber Mar. 2 at 9:10 PM

$XAIR

0 · Reply

BigNik007 Mar. 2 at 11:35 AM

$XAIR Oops, why 0$ at Stocktwits?

0 · Reply

BobintheBuff Mar. 1 at 3:34 PM

$XAIR as I suspected, XTL Bio is not a real company, according to NASDAQ - “based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company’s American Depositary Shares (“ADSs”) is no longer warranted.”

2 · Reply

Say_Whaaaat Feb. 27 at 9:16 PM

$XAIR volume was only 76k on the whole day.... No bueno

1 · Reply

Say_Whaaaat Feb. 26 at 7:38 PM

$XAIR when I look at shares now it's at 10m. Did something happen? It was 17m not that long ago

0 · Reply

BigNik007 Feb. 26 at 8:12 AM

$XAIR Let's do another RS and then drop back again to 1$... Worst investment ever :-D

0 · Reply

DirtDobber Feb. 25 at 7:59 PM

$XAIR what’s up with this shit

1 · Reply

PenkeInvesting Feb. 25 at 4:47 AM

Fundamental analysis of $XAIR (Beyond Air, Inc.) based on financial data and reported results. #XAIR

0 · Reply

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Feb 13, 2026, 10:37 AM EST - 19 days ago

Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript

Feb 13, 2026, 7:30 AM EST - 19 days ago

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Jan 27, 2026, 4:05 PM EST - 5 weeks ago

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Jan 13, 2026, 7:30 AM EST - 7 weeks ago

XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Nov 26, 2025, 4:30 PM EST - 3 months ago

Beyond Air® Announces Transition of Chief Financial Officer

Nov 10, 2025, 6:31 PM EST - 4 months ago

Beyond Air, Inc. (XAIR) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 4 months ago

Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Sep 22, 2025, 8:00 AM EDT - 5 months ago

Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Sep 8, 2025, 3:55 PM EDT - 6 months ago

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:00 AM EDT - 7 months ago

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

Aug 12, 2025, 7:40 PM EDT - 7 months ago

Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript

Jul 25, 2025, 8:00 AM EDT - 7 months ago

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Jul 22, 2025, 7:30 AM EDT - 8 months ago

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

Jun 17, 2025, 9:53 PM EDT - 9 months ago

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 4:32 PM EDT - 9 months ago

Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know

Jun 17, 2025, 4:01 PM EDT - 9 months ago

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Jun 16, 2025, 7:20 AM EDT - 9 months ago

Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

May 20, 2025, 8:00 AM EDT - 10 months ago

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Apr 21, 2025, 4:05 PM EDT - 11 months ago

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Apr 15, 2025, 4:05 PM EDT - 11 months ago

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Apr 9, 2025, 4:05 PM EDT - 11 months ago

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

Mar 24, 2025, 4:05 PM EDT - 1 year ago

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Feb 10, 2025, 7:25 PM EST - 1 year ago

Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript

Feb 10, 2025, 4:05 PM EST - 1 year ago

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 5, 2025, 9:29 AM EST - 1 year ago

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 27, 2025, 4:05 PM EST - 1 year ago

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Jan 24, 2025, 9:15 AM EST - 1 year ago

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

Dec 9, 2024, 11:00 AM EST - 1 year ago

National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products

Dec 3, 2024, 4:05 PM EST - 1 year ago

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

Dec 2, 2024, 7:30 AM EST - 1 year ago

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

Nov 26, 2024, 7:30 AM EST - 1 year ago

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Nov 14, 2024, 4:05 PM EST - 1 year ago

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 11, 2024, 7:56 PM EST - 1 year ago

Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 1 year ago

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2024, 4:22 PM EDT - 1 year ago

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Sep 27, 2024, 7:34 AM EDT - 1 year ago

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

Sep 27, 2024, 7:32 AM EDT - 1 year ago

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

Sep 27, 2024, 7:30 AM EDT - 1 year ago

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Jul 31, 2024, 4:15 PM EDT - 1 year ago

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

Jul 16, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

Jun 24, 2024, 5:48 PM EDT - 1 year ago

Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript

RunningMoons Mar. 4 at 3:15 PM

$MLGO $CREG $PAPL $XAIR u

0 · Reply

VernCapital Mar. 3 at 1:53 PM

$XAIR I’m not sure which part of dead for the rest of 2026 people don’t understand.

1 · Reply

DirtDobber Mar. 2 at 9:10 PM

$XAIR

0 · Reply

BigNik007 Mar. 2 at 11:35 AM

$XAIR Oops, why 0$ at Stocktwits?

0 · Reply

BobintheBuff Mar. 1 at 3:34 PM

2 · Reply

Say_Whaaaat Feb. 27 at 9:16 PM

$XAIR volume was only 76k on the whole day.... No bueno

1 · Reply

Say_Whaaaat Feb. 26 at 7:38 PM

$XAIR when I look at shares now it's at 10m. Did something happen? It was 17m not that long ago

0 · Reply

BigNik007 Feb. 26 at 8:12 AM

$XAIR Let's do another RS and then drop back again to 1$... Worst investment ever :-D

0 · Reply

DirtDobber Feb. 25 at 7:59 PM

$XAIR what’s up with this shit

1 · Reply

PenkeInvesting Feb. 25 at 4:47 AM

Fundamental analysis of $XAIR (Beyond Air, Inc.) based on financial data and reported results. #XAIR

0 · Reply

45IQ Feb. 25 at 4:40 AM

$XAIR $XTLB XTL Approves cap raise and all proposals pertaining to purchasing 85% of neurons. https://www.google.com/amp/s/m.investing.com/news/sec-filings/xtl-biopharmaceuticals-shareholders-approve-share-capital-increase-and-private-placement-93CH-4522757%3fampMode=1

0 · Reply

Tredin3 Feb. 25 at 1:01 AM

$XAIR IBRX’s 1st victim.

1 · Reply

Say_Whaaaat Feb. 21 at 1:22 AM

$XAIR is instution selling bullish?

0 · Reply

Say_Whaaaat Feb. 20 at 1:56 PM

$XAIR lol and nobody even cares. I thought this kind of news would move the needle...

3 · Reply

BullButter23 Feb. 20 at 1:12 PM

$XAIR Potential squeeze… https://www.benzinga.com/pressreleases/26/02/g50745963/beyond-air-comments-on-landmark-independent-review-article-highlighting-the-antimicrobial-effects-

0 · Reply

TheTradeXchange Feb. 20 at 1:01 PM

$XAIR - Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

0 · Reply

DingleberryDandy Feb. 19 at 6:06 PM

$XAIR

1 · Reply

a_s_a_p_Bevo Feb. 19 at 5:55 PM

$XAIR KITT might be on a kite! (Also likes to dump fyi)🙄

0 · Reply

OfficialStocktwitsUser Feb. 16 at 9:51 AM

$XAIR RSI: 20.71, MACD: -0.0631 Vol: 0.30, MA20: 1.31, MA50: 1.15 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

d_risk Feb. 15 at 10:36 PM

$XAIR - Beyond Air, Inc. - 10Q - Updated Risk Factors XAIR flags new deal risk: its planned NeuroNOS acquisition via XTL may not close, potentially leading to sunk costs, strategic uncertainty, financing pressure around NeuroNOS, and downside for the stock. #Healthcare #MergersAndAcquisitions #AcquisitionRisk #FinancingPressure #StockVolatility 🟢 Added 🟠 Removed https://d-risk.ai/XAIR/10-Q/2026-02-13

1 · Reply

Say_Whaaaat Feb. 15 at 4:05 PM

$XAIR hate to be a negative Nancy, be aware .. https://www.tipranks.com/news/company-announcements/analyst-warns-failure-of-neuronos-acquisition-could-pressure-beyond-airs-strategy-finances-and-stock-price?utm_source=webullapp.com&utm_medium=referral

2 · Reply

maixem Feb. 15 at 5:13 AM

$XAIR waiting for reversal before entry

0 · Reply

Market Cap	9.38M
Revenue (ttm)	3.71M
Net Income (ttm)	-46.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,256.87%
Debt to Equity Ratio	2.65

Volume	124,800
Avg Vol	9,151,396
Day's Range	N/A - N/A
Shares Out	10.53M
Stochastic %K	30%
Beta	0.41
Analysts	Strong Sell
Price Target	$6.00